Cutler Group LP Cellectis S.A. Transaction History

Cutler Group LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 18, 2024	BUY	$0.97 - $3.55 $194 - $710	200 New	200 $0
Q4 2018 Feb 05, 2019	SELL	$15.58 - $28.41 $7,790 - $14,205	-500 Closed	0 $0
Q3 2018 Nov 07, 2018	SELL	$25.99 - $30.6 $4,210 - $4,957	-162 Reduced 24.47%	500 $14,000
Q2 2018 Aug 10, 2018	BUY	$27.78 - $38.53 $15,612 - $21,653	562 Added 562.0%	662 $18,000
Q1 2018 May 11, 2018	SELL	$27.78 - $35.19 $41,670 - $52,785	-1,500 Reduced 93.75%	100 $3,000

Q4 2017 Jan 17, 2018	BUY	$23.33 - $35.01 $32,172 - $48,278	1,379 Added 623.98%	1,600 $46,000
Q3 2017 Oct 17, 2017	BUY	$21.65 - $32.18 $4,784 - $7,111	221	221 $6,000

9.83M

30.9K

Ticker CLLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,510,800
Market Cap $88.7M
Description
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.